Evidence map›Paper›PMID 38779144›Full record

ArticleIDCases2024

Acquired bedaquiline and fluoroquinolones resistance during treatment follow-up in Oromia Region, North Shewa, Ethiopia.

Getu Diriba, Ayinalem Alemu, Betselot Zerihun Ayano, Bazezew Yenew, Michael Hailu, Bedo Buta, Amanuel Wondimu, Zigba Tefera, Zerihun Ababu, Yerosen Ebisa and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Getu DiribaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Ayinalem AlemuEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Betselot Zerihun AyanoEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Bazezew YenewEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Michael HailuEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Bedo ButaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Amanuel WondimuEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Zigba TeferaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Zerihun AbabuChancho Primary Hospital, Chancho, Ethiopia.
Yerosen EbisaChancho Primary Hospital, Chancho, Ethiopia.
Shewki MogaEthiopian Public Health Institute, Addis Ababa, Ethiopia.
Gemechu TadesseEthiopian Public Health Institute, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bedaquiline (BDQ) is an effective drug currently used for multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) and pre-extensively drug-resistant TB (pre-XDR-TB) treatment. However, resistance to this new drug is emerging. We discussed the characteristics of the first patient in Ethiopia who acquired BDQ and fluoroquinolones (FQs) resistance during treatment follow-up. Case report: In this case report, we present the case of a 28-year-old male pulmonary TB patient diagnosed with MDR-TB who is a resident of the Oromia Region of North Shewa, Mulona Sululta Woreda, Ethiopia. Sputum specimen was collected initially and for treatment monitoring using culture and for phenotypic drug susceptibility testing (DST) to first-line and second-line TB drugs. Initially, the patient was infected with a mycobacterial strain resistant to the first-line anti-TB drugs Rifampicin (RIF), Isoniazid (INH), and Pyrazinamide (PZA). Later, during treatment, he acquired additional drug resistance to ethambutol (EMB), ofloxacin (OFX), levofloxacin (LFX), moxifloxacin (MFX), and BDQ. The patient was tested with MTBDR Conclusion: This case report data has revealed the evolution of BDQ resistance during treatment with a BDQ-containing regimen in Ethiopia. Therefore, there is a need for DST to new second-line drugs to monitor and prevent the spread of DR-TB.

Indexed as

Acquired resistanceBedaquilineFluoroquinolonesMultidrug-Resistant TuberculosisTuberculosis

Identifiers

PMID38779144
PMCPMC11109312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.